Perturbation of lipids and glucose metabolism associated with previous 2,4-D exposure: A cross-sectional study of NHANES III data, 1988-1994

Environmental Health: A Global Access Science Source

Volumn 9, Issue 1, 2010, Pages

  Schreinemachers, Dina M ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DICHLOROPHENOXYACETIC ACID; C PEPTIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; THYROTROPIN; THYROXINE; TRIACYLGLYCEROL; GLYCOSYLATED HEMOGLOBIN; HDL TRIGLYCERIDE; HDL-TRIGLYCERIDE; HERBICIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; URINE LEVEL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GLUCOSE BLOOD LEVEL; METABOLISM; NUTRITION; STATISTICAL MODEL; URINE;

TRITICUM AESTIVUM;

2,4-DICHLOROPHENOXYACETIC ACID; ADULT; BLOOD GLUCOSE; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; ENVIRONMENTAL EXPOSURE; FEMALE; GLUCOSE METABOLISM DISORDERS; HEMOGLOBIN A, GLYCOSYLATED; HERBICIDES; HUMANS; LINEAR MODELS; LIPIDS; LIPOPROTEINS, HDL; MALE; NUTRITION SURVEYS; THYROXINE; TRIGLYCERIDES;

EID: 77950857103     PISSN: None     EISSN: 1476069X     Source Type: Journal    
DOI: 10.1186/1476-069X-9-11     Document Type: Article

References (58)

1. Short P, Colborn T: Pesticide use in the U.S. and policy implications: a focus on herbicides. Toxicol Ind Health 1999, 15:240-275.
2. Huwe JK, Clark GC, Chu AC, Garry V: Calux and high resolution GC/MS analysis of dioxin-like compounds in chlorophenoxy pesticide formulations. Organohalogen Compounds 2003, 60:227-230.
3. USDA 1998 Forest Service: 2,4-Dichlorophenoxyacetic acid Formulations-Human Health and Ecological Risk Assessment. Final Report. [http://www.fs.fed.us/foresthealth/pesticide/pdfs/093006-24d.pdf].
4. Waite DT, Bailey P, Sproull JF, Quiring DV, Chau DF, Bailey J, Cessna AJ: Atmospheric concentrations and dry and wet deposits of some herbicides currently used on the Canadian Prairies. Chemosphere 2005, 58:693-703.
5. Waite DT, Cessna AJ, Grover R, Kerr LA, Snihura AD: Environmental concentrations of agricultural herbicides: 2,4-D and triallate. J Environ Qual 2002, 31:129-144.
6. Nishioka MG, Burkholder HM, Brinkman MC, Gordon SM: Measuring transport of lawn-Applied herbicide acids from turf to home: 2,4-D turf residues with carpet dust and carpet surface residues. Environ Sci Technol 1996, 30:3313-3320.
7. Donald DB, Cessna AJ, Sverko E, Glozier NE: Pesticides in surface drinking water supplies of the northern Great Plains. Environ Health Perspect 2007, 115:1183-1191.
8. Gilliom RJ, Barbash JE, Crawford CG, Hamilton PA, Martin JD, Nakagaki N, Nowell LH, Scott JC, Stackelberg PE, Thelin GP, Wolock DM: The quality of our Nation's Waters. Pesticides in the Nation's Streams and Ground Water, 1992-2001. U.S. Geologic Survey Circular 1291. U.S. Washington DC, Department of the Interior 2006.
9. Toxic Air Pollutants. U.S. Environmental Protection Agency 2006 [http://www.epa.gov/ttn/atw/188polls.html].
10. Drinking Water Contaminants. U.S. Environmental Protection Agency 2008 [http://www.epa.gov/safewater/contaminants/index.html].
11. Lin BH, Padgitt M, Bull L, Delvo H, Shank D, Taylor H: Pesticide and fertilizer use and trends in U.S. Agriculture. An economic service report. Agricultural Economic Report No 717 Washington, DC. U.S. Department of Agriculture 1995.
12. Garry VF, Schreinemachers D, Harkins ME, Griffith J: Pesticide appliers, biocides, and birth defects in rural Minnesota. Environ Health Perspect 1996, 104:394-399.
13. Schreinemachers DM, Creason JP, Garry VF: Cancer mortality in agricultural regions of Minnesota. Environ Health Perspect 1999, 107:205-211.
14. Schreinemachers DM: Cancer mortality in four northern wheat-producing states. Environ Health Perspect 2000, 108:873-881.
15. Schreinemachers DM: Birth malformations and other adverse perinatal outcomes in four U.S. wheat-producing states. Environ Health Perspect 2003, 111:1259-1264.
16. Schreinemachers DM: Mortality from ischemic heart disease and diabetes mellitus (type 2) in four U.S. wheat-producing states: a hypothesisgenerating study. Environ Health Perspect 2006, 114:186-193.
17. Toxicity testing in the twenty-first century: a vision and a strategy. National Academy of Sciences, National Research Council, Committee on Toxiciy Testing and Assessment of Environmental Agents. Board on Environmental Studies and Toxicology The National Academies Press, Washington, DC 2007.
18. Priority Toxicant Reference Range Data File, Third National Health and Nutrition Examination Survey (NHANES III), 1988-94. National Center for Health Statistics, Hyattsville, MD 2000.
19. Duntas LH: Subclinical thyroid disorders: The menace of the Trojan horse. J Endocrinol Invest 2003, 26:472-480.
20. Ingelsson E, Arnlöv J, Sundström J, Zethelius B, Vessby B, Lind L: Novel metabolic risk factors for heart failure. J Am Coll Cardiol 2005, 46:2054-2060.
21. Axelson O, Tagesson C, Hardell L: The clofibrate problem: a different viewpoint. The Lancet ii 1980, 1081-1082.
22. Vainio H, Linnainmaa K, Kähönen M, Nickels J, Hietanen E, Marniemi J: Hypolipidemia and peroxisome proliferation induced by phenoxyaceic acid herbicides in rats. Biochem Pharmacol 1983, 32:2775-2779.
23. Menuet R, Lavie CJ, Milani RV: Importance and management of dyslipidemia in the metabolic syndrome. Am J Med Sci 2005, 330:295-302.
24. Miller M, Langenberg P, Havas S: Impact of lowering triglycerides on raising HDL-C in hypertriglyceridemic and non-hypertriglyceridemic subjects. Int J Cardiol 2007, 119:192-195.
25. Hill RH, Shealy DB, Head SL, Williams CC, Bailey SL, Gregg M, Baker SE, Needham LL: Determination of pesticide metabolites in human urine using isotope dilution technique and tandem mass spectrometry. J Analyt Toxicol 1995, 19:323-329.
26. SAS/STAT Guide for Personal Computers: Version 9.1 SAS Institute, Inc. Cary, NC 2001.
27. Duntas LH, Wartofsky L: Cardiovascular risk and subclinical hypothyroidism: Focus on lipids and new emerging risk factors. What is the evidence? Thyroid 2007, 17:1075-1084.
28. Ito M, Arishima T, Kudo T, Nishihara E, Ohye H, Kubota S, Fukata S, Amino N, Kuma K, Sasaki I, Hiraiwa T, Hanafusa T, Takamatsu J, Miyauchi A: Effect of levo-thyroxine replacement on non-high density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab 2007, 92:608-611.
29. Greenland S: Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989, 79:340-349.
30. Vineis P, Khan AE, Vlaanderen J, Vermeulen R: The impact of new research technologies on our understanding of environmental causes of disease: the concept of clinical vulnerability. Environ Health 2009, 8:54.
31. Chapman MJ: Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther 2006, 111:893-908.
32. Parhofer KG: Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention. Exp Clin Endocrinol Diabetes 2005, 113:414-417.
33. Sierksma A, Gaag van der MS, van Tol A, James RW, Hendriks HFJ: Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res 2002, 26:1430-1435.
34. Mastorakis G, Karoutsou EI, Mizamtsidi M, Creatsas G: The menace of endocrine disruptors on thyroid hormone physiology and their impact on intrauterine development. Endocr 2007, 31:219-237.
35. Berg Van den KJ, van Raaij JAGM, Bragt PC, Notten WRF: Interactions of halogenated industrial chemicals with transthyretin and effects on thyroid hormone levels in vivo. Arch Toxicol 1991, 65:15-19.
36. Duntas LH: Thyroid disease and lipids. Thyroid 2002, 12:287-294.
37. Franco M, Castro G, Romero L, Regalado JC, Medina A, Huesca-Gómez C, Ramírez S, Montaño LF, Posadas-Romero C, Pérez-Méndez O: Decreased activity of lecithin:cholesterol acyltransferase and hepatic lipase in chronic hypothyroid rats: Implications for reverse cholesterol transport. Mol Cell Biochem 2003, 246:51-56.
38. Pearce EN: Hypothyroidism and dislipidemia: Modern concepts and approaches. Current Cardiology Reports 2004, 6:451-456.
39. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J: Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocr 2004, 61:232-238.
40. Rodondi N, Aujesky D, Vittinghoff E, Cornuz J, Bauer DC: Subclinical hypothyroidism and the risk of coronary heart disease: a meta-Analysis. Am J Med 2006, 119:541-551.
41. Wierzbicki AS: Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin 2005, 21:299-305.
42. Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C: Raising highdensity lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid: a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004, 20:1253-1268.
43. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G: Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003, 139:802-809.
44. Parhofer KG: Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention. Exp Clin Endocrinol Diabetes 2005, 113:414-417.
45. Sacks FM for the Expert Group on HDL Cholesterol: The role of highdensity lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: Expert Group recommendations. Am J Cardiol 2002, 90:139-143.
46. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V: Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 western prospective studies. Circulation 2007, 115:450-458.
47. Wierzbicki AS, Mikhailidis DP: Beyond LDL-C-The importance of raising HDL-C. Curr Med Res Opin 2002, 18:36-44.
48. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM: Fibrates: What have we learned in the past 40 years? Pharmacotherapy 2007, 27:412-424.
49. Dierkes J, Luley C, Westphal S: Effect of lipid-lowering and antihypertensive drugs on plasma homocysteine levels. Vasc Health Risk Manag 2007, 3:99-108.
50. Fruchart JC: The science behind statins and fibrates. Int J Clin Practice 2002, 132(Suppl):11-16.
51. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC: Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998, 98:2088-2093.
52. Park BH, Breyer BB, He TC: Peroxisome proliferator-Activated receptors: roles in tumorigenesis and chemoprevention in human cancer. Curr Opin Oncol 2001, 13:78-83.
53. Dierkes J, Westphal S, Luley C: Effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. Expert Opin Drug Saf 2004, 3:101-111.
54. Wierzbicki AS: FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract 2006, 60:442-449.
55. Luci S, Kluge H, Hirche F, Eder K: Clofibrate increases hepatic triiodothyronine (T3)-And thyroxine (T4)-glucuronosyltransferase activities and lowers plasma T3 and T4 concentrations in pigs. Drug Metabol Disp 2006, 34:1887-1892.
56. Schuck JR, Chappell LT, Kindness G: Causal modeling and alternative medicine. Altern Ther Health Med 1997, 3:40-47.
57. Flanders WD, Lin L, Pirkle JL, Caudill SP: Assessing the direction of causality in cross-sectional studies. Am J Epidemiol 1992, 135:926-935.
58. Pekkanen J, Pearce N: Environmental epidemiology: challenges and opportunities. Environ Health Perspect 2001, 109:1-5.